Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

被引:300
作者
Merzon, Eugene [1 ,2 ]
Tworowski, Dmitry [3 ]
Gorohovski, Alessandro [3 ]
Vinker, Shlomo [1 ,2 ]
Cohen, Avivit Golan [1 ,2 ]
Green, Ilan [1 ,2 ]
Frenkel-Morgenstern, Milana [3 ]
机构
[1] Leumit Hlth Serv, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dept Family Med, Tel Aviv, Israel
[3] Bar Ilan Univ, Azrieli Fac Med, Canc Genom & BioComp Complex Dis Lab, Henrietta Szold 8, IL-13151 Safed, Israel
关键词
COVID-19; Israeli population study; low plasma 25(OH) vitamin D level; risk of infection; vitamin D; D DEFICIENCY; D SUPPLEMENTATION; SARS-COV-2; DIAGNOSIS; DISEASES; REGISTRY;
D O I
10.1111/febs.15495
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Vitamin D deficiency is a worldwide pandemic. The aim of this study was to evaluate associations of plasma 25(OH)D levels with the likelihood of coronavirus disease 2019 (COVID-19) infection and hospitalization. The study population included the 14 000 members of Leumit Health Services, who were tested for COVID-19 infection from February 1(st)to April 30(th), 2020, and who had at least one previous blood test for the plasma 25(OH)D level. 'Suboptimal' or 'low' plasma 25(OH)D level was defined as plasma 25-hydroxyvitamin D, or 25(OH)D, concentration below the level of 30 ng/mL. Of 7807 individuals, 782 (10.02%) were COVID-19-positive, and 7025 (89.98%) COVID-19-negative. The mean plasma vitamin D level was significantly lower among those who tested positive than negative for COVID-19 [19.00 ng/mL(1)(95% confidence interval (CI) 18.41-19.59) vs. 20.55 (95% CI: 20.32-20.78)]. Univariate analysis demonstrated an association between the low plasma 25(OH)D level and increased likelihood of COVID-19 infection [crude odds ratio (OR) of 1.58 (95% CI: 1.24-2.01,P < 0.001)], and of hospitalization due to the SARS-CoV-2 virus [crude OR of 2.09 (95% CI: 1.01-4.30,P < 0.05)]. In multivariate analyses that controlled for demographic variables, and psychiatric and somatic disorders, the adjusted OR of COVID-19 infection [1.45 (95% CI: 1.08-1.95,P < 0.001)] and of hospitalization due to the SARS-CoV-2 virus [1.95 (95% CI: 0.98-4.845,P = 0.061)] were preserved. In the multivariate analyses, age over 50 years, male gender and low-medium socioeconomic status were also positively associated with the risk of COVID-19 infection; age over 50 years was positively associated with the likelihood of hospitalization due to COVID-19. We concluded that low plasma 25(OH)D levels appear to be an independent risk factor for COVID-19 infection and hospitalization.
引用
收藏
页码:3693 / 3702
页数:10
相关论文
共 64 条
[1]
Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review [J].
Adhikari, Sasmita Poudel ;
Meng, Sha ;
Wu, Yu-Ju ;
Mao, Yu-Ping ;
Ye, Rui-Xue ;
Wang, Qing-Zhi ;
Sun, Chang ;
Sylvia, Sean ;
Rozelle, Scott ;
Raat, Hein ;
Zhou, Huan .
INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
[2]
Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
[3]
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast [J].
Almerie, Muhammad Qutayba ;
Kerrigan, David Daniel .
MEDICAL HYPOTHESES, 2020, 143
[4]
Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis [J].
Alqahtani, Jaber S. ;
Oyelade, Tope ;
Aldhahir, Abdulelah M. ;
Alghamdi, Saeed M. ;
Almehmadi, Mater ;
Alqahtani, Abdullah S. ;
Quaderi, Shumonta ;
Mandal, Swapna ;
Hurst, John R. .
PLOS ONE, 2020, 15 (05)
[5]
[Anonymous], 2020, EUR J INTERN MED, DOI DOI 10.1016/J.EJIM.2020.05.033
[6]
[Anonymous], 2018, ENFERM INFEC MICR CL, DOI DOI 10.1016/J.EIMC.2017.03.009
[7]
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 [J].
Bagca, Bakiye Goker ;
Avci, Cigir Biray .
CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 54 :51-61
[8]
Cao Zhijian, 2020, Infectious Disorders - Drug Targets, V20, P348, DOI 10.2174/1871526520999200505174704
[9]
A new clinical trial to test high-dose vitamin C in patients with COVID-19 [J].
Carr, Anitra C. .
CRITICAL CARE, 2020, 24 (01)
[10]
Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic [J].
Carter, Stephen J. ;
Baranauskas, Marissa N. ;
Fly, Alyce D. .
OBESITY, 2020, 28 (07) :1176-1177